Cooper Health System

1. Baxter Healthcare $54,943 6 payments
2. Eisai Inc. $46,305 5 payments
3. Seattle Genetics, Inc. $46,156 3 payments
4. Biogen, Inc. $39,052 3 payments
5. Bayer HealthCare Pharmaceuticals Inc. $14,190 4 payments
6. ViiV Healthcare Company $9,660 8 payments
7. GlaxoSmithKline, LLC. $5,760 8 payments
8. Gynesonics, Inc. $3,339 2 payments
9. Novartis Pharmaceuticals Corporation $790 2 payments
10. AstraZeneca Pharmaceuticals LP $500 1 payment

1. Starling Registry $54,943 6 payments
2. A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR??)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types $46,305 5 payments
3. A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) $46,156 3 payments
4. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy $39,052 3 payments
5. BAY 1841788, mHSPC $12,940 1 payment
6. PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $7,016 6 payments
7. A 5-Year Prospective Observational Registry to Assess Adverse Events O $5,760 8 payments
8. Sonata $3,339 2 payments
9. A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $2,645 2 payments
10. 060204 - Clinical Trial Pase IV (Post Marketing) (Bayer Product or TA) $1,250 3 payments

1. Other $54,943 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.